Novel Sigma Receptor Ligand-Nitric Oxide Photodonors: Molecular Hybrids for Double-Targeted Antiproliferative Effect

J Med Chem. 2017 Dec 14;60(23):9531-9544. doi: 10.1021/acs.jmedchem.7b00791. Epub 2017 Dec 4.

Abstract

This contribution reports the synthesis and evaluation of novel hybrid compounds that conjugate a sigma (σ) receptor pharmacophore and a nitric oxide (NO) photodonor. All compounds preserve their capability to generate NO under visible light and possess overall σ receptor nanomolar affinity, with one of them (8b) exhibiting remarkable σ2 receptor selectivity. Compounds 8b, 11a, and 11b were tested on tumorigenic MCF-7 and A2058 cells expressing high levels of σ2 and σ1 receptor, respectively. Considerable loss of cell viability was detected under light excitation, while negligible effects in the dark were detected. Moreover, they did not show any significant cytotoxicity in the dark or under irradiation on nontumorigenic NCTC-2544 keratinocytes. NO-induced reduction of cellular viability was demonstrated by in-cell NO detection and total nitrite estimation. For the first time, a combination of σ receptor moieties and a NO photodonor is reported, providing distinctive ligands potentially useful for cancer management.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Cell Line
  • Cell Proliferation / drug effects*
  • Cell Survival / drug effects
  • Humans
  • Light
  • MCF-7 Cells
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Nitric Oxide / metabolism
  • Nitric Oxide Donors / chemistry*
  • Nitric Oxide Donors / pharmacology*
  • Photochemotherapy
  • Photosensitizing Agents / chemistry
  • Photosensitizing Agents / pharmacology
  • Receptors, sigma / metabolism*

Substances

  • Antineoplastic Agents
  • Nitric Oxide Donors
  • Photosensitizing Agents
  • Receptors, sigma
  • Nitric Oxide